CureVac N.V. (NASDAQ: CVAC) stock fell -6.12% on Wednesday to $9.82 against a previous-day closing price of $10.46. With 0.75 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.54 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $10.55 whereas the lowest price it dropped to was $9.41. The 52-week range on CVAC shows that it touched its highest point at $19.67 and its lowest point at $5.63 during that stretch. It currently has a 1-year price target of $16.43.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CVAC was up-trending over the past week, with a rise of 7.91%, but this was up by 35.45% over a month. Three-month performance surged to 13.39% while six-month performance rose 23.52%. The stock lost -48.56% in the past year, while it has gained 62.85% so far this year. A look at the trailing 12-month EPS for CVAC yields -1.33 with Next year EPS estimates of -0.66. For the next quarter, that number is -0.34. This implies an EPS growth rate of 42.00% for this year and 39.00% for next year.
Float and Shares Shorts:
At present, 216.34 million CVAC shares are outstanding with a float of 88.88 million shares on hand for trading. On Apr 27, 2023, short shares totaled 3.61 million, which was 1.61% higher than short shares on Mar 30, 2023. In addition to Mr. Pierre Kemula B.Sc. as the firm’s MD, CFO & Member of Management Board, Dr. Igor Splawski M.Sc., Ph.D. serves as its Chief Scientific Officer & Member of Management Board.
Through their ownership of 24.44% of CVAC’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 2.64% of CVAC, in contrast to 13.40% held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in CVAC with 5.47% of the stake, RA Capital Management LP holds 12,245,955 shares worth 12,245,955. A second-largest stockholder of CVAC, T. Rowe Price Associates, Inc., holds 3,813,896 shares, controlling over 1.70% of the firm’s shares. Avidity Partners Management LP is the third largest shareholder in CVAC, holding 3,550,000 shares or 1.59% stake. With a 0.63% stake in CVAC, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 1,399,211 shares are owned by the mutual fund manager. The iShares Biotechnology ETF, which owns about 0.30% of CVAC stock, is the second-largest Mutual Fund holder. It holds 673,740 shares valued at 4.97 million. Government Pension Fund – Global holds 0.22% of the stake in CVAC, owning 490,897 shares worth 3.62 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Dec 30, 2022, CVAC reported revenue of $20.15M and operating income of -$61.22M. The EBITDA in the recently reported quarter was -$49.40M and diluted EPS was -$0.08.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CVAC since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CVAC analysts setting a high price target of $22.29 and a low target of $9.09, the average target price over the next 12 months is $15.11. Based on these targets, CVAC could surge 126.99% to reach the target high and fall by -7.43% to reach the target low. Reaching the average price target will result in a growth of 53.87% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.